ClinicalTrials.gg
Active, not recruitingNCT06180278N-MOmentum LTUpdated Nov 21, 2025

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

A Phase 4 interventional study of Blood tests and Inebilizumab in Neuromyelitis Optica Spectrum Disorder, sponsored by Amgen. Active, not recruiting at 11 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Neuromyelitis Optica with a site in Korea, Republic of — 2 open to participants now, 4 under way, 1 of them phase 3. Neuromyelitis Optica · Korea, Republic of.

Enrollment
7th of 10
32 · median 77
Started
2024
with 1 other
Phase 4
2 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Amgen

Among the 12 studies in Neuromyelitis Optica with a site in Korea, Republic of, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 11th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

2 of the 12 studies in Neuromyelitis Optica with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Neuromyelitis Optica with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins and B-cell counts in participants with NMOSD who discontinue treatment. The objectives include:

  1. To establish the nadir in circulating immunoglobulins (Ig) during chronic treatment with inebilizumab and ascertain the time needed to ensure restoration of pre-treatment baseline serum levels of IgG and IgM after discontinuation of treatment
  2. To characterize B-cell counts throughout treatment with inebilizumab and after discontinuation until repletion of Immunoglobulin (Ig levels)
  3. To assess long-term safety of inebilizumab
  4. To assess other long-term effects of inebilizumab
Read the detailed description

This study aims to enroll 30 participants who either participated in the open-label period (OLP) of the N-MOmentum study (CD-IA-MEDI-551-1155; NCT02200770), a global registrational study that determined the safety and efficacy of inebilizumab for treatment of NMOSD, or who are newly initiating inebilizumab treatment at the discretion of their physician at participating sites.

Acquired from Horizon in 2024.

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder

Browse trials for

Keywords

  • Immunoglobulins
  • B-cell count
  • inebilizumab
  • Uplizna
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or above, and able to provide written and any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA] in the United States of America (USA), European Union [EU] Data Privacy Directive in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations.
  2. Have completed at least 2 years in the open-label period of the N-MOmentum study or are newly initiating inebilizumab treatment at a participating site.
  3. Females of who are sexually active with a nonsterilized male partner must use a highly effective method of as outlined in the protocol (subjects in the Czech Republic only must use 1 additional method of contraception) from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab; cessation of contraception after this point should be discussed with a responsible physician.
  4. Nonsterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide (subjects in the Czech Republic only must use 1 additional method of contraception) from Day 1 for 3 months after receipt of last treatment with inebilizumab.
  5. Sterilized males, without the appropriate post-vasectomy documentation on the absence of sperm in the ejaculate, who are sexually active with a female partner of childbearing potential must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab.

Exclusion criteria

Exclusion Criteria:

  1. Have any condition that would place the participant at unacceptable risk of complications, interfere with evaluation of inebilizumab or confound the interpretation of participant safety or study results.
  2. Received rituximab or any other B-cell depleting agent after exit from N-MOmentum study, or within the last 12 months prior to screening for non N-MOmentum participants.
  3. Known history of allergy or reaction to any component of inebilizumab formulation or history of anaphylaxis following any biologic therapy
  4. Have a severe infection, including active chronic infection such as
  5. Have active or untreated latent tuberculosis
  6. Have a history of progressive multifocal leukoencephalopathy (PML)
  7. Is severely state
  8. Have active
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Other
    Participants with NMOSD exposed to inebilizumab

    Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.

    Other: Blood tests · Drug: Inebilizumab

Interventions

  • OtherBlood tests

    Participants will have blood tests done at each scheduled visit (approximately every 6 months).

  • Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.

    Also known as: UPLIZNA

06

What researchers measure

Primary outcomes

  1. Change from baseline in serum Ig levels (total Ig, IgG, IgM, IgA, IgE) over time

    This will be assessed via serum samples, drawn at the site and processed at a central laboratory, and analyses performed to assess change from baseline over time, as measured by each parameter in mg/dL

    Time frame: Up to 42 months

  2. Change from baseline in peripheral CD20+ B-cell counts over time

    This will be assessed via serum samples, drawn at the site and processed at a central laboratory, and analyses performed to assess change from baseline over time, as measured by each parameter in cells/mL

    Time frame: Up to 42 months

Secondary outcomes

  1. Change from baseline in hematology over time

    The lab parameters being assessed as part of the hematology analyses include the following: platelet count, red blood cell count, other indices of red blood cells, including MCV (mean corpuscle volume), MCH (mean corpuscle hemoglobin), % reticulocyte count, and morphology (shape); white blood count with differential, including neutrophil count, Lymphocyte count, monocyte count, eosinophils, and basophils; hemoglobin and hematocrit.

    Time frame: Up to 42 months

  2. Change from baseline in clinical chemistry over time

    The lab parameters being assessed as part of clinical chemistry include blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase.

    Time frame: Up to 42 months

  3. Incidence of serious infections

    Time frame: Up to 42 months

  4. Incidence of viral reactivation

    Time frame: Up to 42 months

  5. Incidence of progressive multifocal leukoencephalopathy (PML)

    Time frame: Up to 42 months

  6. Incidence of other opportunistic infections

    Time frame: Up to 42 months

  7. Incidence of malignancies

    Time frame: Up to 42 months

  8. Incidence of infusion reactions

    Time frame: Up to 42 months

  9. Number of protocol-defined NMOSD attacks

    Time frame: Up to 42 months

  10. Percentage of protocol-defined NMOSD attacks

    Time frame: Up to 42 months

  11. Incidence of Anti-drug antibody (ADA) directed against Inebilizumab status and titers

    Time frame: Up to 42 months

07

Study locations

11 sites
  • Wayne State University School of Medicine
    Detroit, Michigan 48201-2153, United States
  • Baylor College of Medicine
    Houston, Texas 77030-4202, United States
  • Prince of Wales Hospital (PWH) - The Chinese University of Hong Kong (CUHK) - Ophtalmology
    Hong Kong, 0000, China
  • Vseobecna fakultni nemocnice v Praze - Neurologicka klinika
    Prague, 128 21, Czechia
  • Szegedi Tudományegyetem, à OK, Szent-Györgyi Albert Klinikai Központ - Neurológiai Osztály
    Szeged, Csongrád megye 6725, Hungary
  • Uniwersyteckie Centrum Kliniczne WUM - Oddzial Kliniczny Neurologii
    Warsaw, Masovian Voivodeship 02-057, Poland
  • M.A.-Lek A.M. Maciejowscy S.C. Centrum Terapii SM
    Katowice, Silesian Voivodeship 40-751, Poland
  • National Cancer Center - Neurology Clinic
    Goyang-si, Gyeonggido [Kyonggi-do] 10408, South Korea
  • Seoul National University Hospital
    Seoul, Seoul Teugbyeolsi [Seoul-T'ukp 03080, South Korea
  • Samsung Medical Center - Pediatric Neurology
    Seoul, Seoul Teugbyeolsi [Seoul-T'ukp 6351, South Korea
  • Khon Kaen University, Srinagarind Hospital - Division of Neurology, Depart
    Khon Kaen, 40002, Thailand
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jun 2028, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Dec 22, 2023
StartActual
Apr 2, 2024
Primary completionEst.
Jun 26, 2028
CompletionEst.
Jun 26, 2028
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06180278
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 22, 2023
Start date
Apr 2, 2024
Primary completion
Jun 26, 2028 (estimated)
Completion
Jun 26, 2028 (estimated)
Last update
Nov 21, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion